Vas Narasimhan

Latest articles

12d
Stamford Advocate
Drug giant Novartis is going after a $5 billion eye-drug marketinto the eye. Novartis' drug would be given once every three months, while Eyle
Stamford Advocate / Posted 12 days ago
into the eye. Novartis' drug would be given once every three months, while Eylea is injected once every eight weeks. Vas Narasimhan, the incoming CEO of Novartis and the current global head of drug development and chief medical officer, told... Read more
2 related articles
12d
Connecticut Post
Drug giant Novartis is going after a $5 billion eye-drug marketinto the eye. Novartis' drug would be given once every three months, while Eyle
Connecticut Post / Posted 12 days ago
into the eye. Novartis' drug would be given once every three months, while Eylea is injected once every eight weeks. Vas Narasimhan, the incoming CEO of Novartis and the current global head of drug development and chief medical officer, told... Read more
2 related articles
12d
Business Insider
Drug giant Novartis is going after a $5 billion eye-drug marketinto the eye. Novartis' drug would be given once every three months, while Eyle
Business Insider / Posted 12 days ago
into the eye. Novartis' drug would be given once every three months, while Eylea is injected once every eight weeks. Vas Narasimhan, the incoming CEO of Novartis and the current global head of drug development and chief medical officer, told... Read more
2 related articles
12d
Channel NewsAsia
Novartis posts eye drug data amid play for Eylea's turfsells in the United States. "When you take all of that together ... we believe
Channel NewsAsia / Posted 12 days ago
sells in the United States. "When you take all of that together ... we believe we have a very compelling proposition," Vas Narasimhan, Novartis's chief drug developer who will become CEO in 2018, said on a conference call. Novartis, which... Read more
20d
Fortune
We've Had Terrible Luck Trying to Cure Alzheimer's. But What If We Could Prevent It?Alzheimer’s disease,” said Novartis’ chief medical officer, global head of drug
Fortune / Posted 20 days ago
Alzheimer’s disease,” said Novartis’ chief medical officer, global head of drug development, and soon-to-be CEO Dr. Vas Narasimhan in a statement. “If we determine that our [treatment] can prevent or delay the onset of symptoms in healthy... Read more
23d
Channel NewsAsia
Novartis asks FDA to expand Kymriah's use against blood cancerimmunotherapy and we are committed to bringing this innovation to as many patie
Channel NewsAsia / Posted 23 days ago
immunotherapy and we are committed to bringing this innovation to as many patients who may benefit as possible," Vas Narasimhan, Novartis's chief medical officer and designated CEO, said in a statement. With CAR-T therapies, patients'... Read more
30d
Reuters
Novartis aims to beef up Alcon before possible 2019 spin offkeep. “What we would be considering right now is a separate listing,” Jimenez,
Reuters / Posted 30 days ago
keep. “What we would be considering right now is a separate listing,” Jimenez, who on Feb. 1 will hand over the CEO job to Vas Narasimhan, told reporters on a call. “A standalone company with a separate listing, and those shares would go to our... Read more
6 related articles
30d
Swissinfo
Novartis Plans to Give Ailing Alcon More Time for Turnaroundquarterly profit increase in almost three years. Chief Executive Officer Joe J
Swissinfo / Posted 30 days ago
quarterly profit increase in almost three years. Chief Executive Officer Joe Jimenez, who is set to hand the reins to Vas Narasimhan after eight years at the helm, has said he expects the company to return to growth next year. Alcon, which has... Read more
6 related articles

In this news